Teva Under Investigation For Creating ‘False Perceptions’ Of Generics

Teva Pharmaceutical Industries Ltd. is the subject of a new antitrust investigation by the European Commission looking at whether the Israeli company artificially extended the market exclusivity of its multiple sclerosis drug Copaxone and also whether it embarked on a campaign to “create a false perception of health risks” with regard to generic competition.

According to the commission, Teva’s actions, if proven, could be an abuse of dominant position, which would infringe Article 102 of the treaty on the Functioning of the European Union...